Literature DB >> 16036074

Use of highly potent bisphosphonates in the treatment of osteoporosis.

Michael McClung1.   

Abstract

Bisphosphonates are effective inhibitors of bone remodeling. In the clinical setting, these agents prevent bone loss, preserve bone architecture, and improve bone strength. Clinically significant reduction in the risk of spine and nonspine fractures is observed in patients known to be at risk for fracture. When administered appropriately, these drugs are well tolerated and have an excellent safety profile. Potent bisphosphonates are now the preferred treatment option to reduce the fracture risk in men and women with involutional and glucocorticoid-induced osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 16036074     DOI: 10.1007/s11914-996-0006-5

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  50 in total

Review 1.  Use of bisphosphonates in the prevention of bone loss and fractures.

Authors:  A M Parfitt
Journal:  Am J Med       Date:  1991-11-25       Impact factor: 4.965

2.  Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

Authors:  L Mortensen; P Charles; P J Bekker; J Digennaro; C C Johnston
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

3.  Hypoparathyroidism unmasked by alendronate.

Authors:  A S Kashyap; S Kashyap
Journal:  Postgrad Med J       Date:  2000-07       Impact factor: 2.401

Review 4.  Zoledronic acid.

Authors:  S M Cheer; S Noble
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

Authors:  H A Pols; D Felsenberg; D A Hanley; J Stepán; M Muñoz-Torres; T J Wilkin; G Qin-sheng; A M Galich; K Vandormael; A J Yates; B Stych
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

6.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

Authors:  G Y Boivin; P M Chavassieux; A C Santora; J Yates; P J Meunier
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

7.  Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.

Authors:  D C Bauer; D Black; K Ensrud; D Thompson; M Hochberg; M Nevitt; T Musliner; D Freedholm
Journal:  Arch Intern Med       Date:  2000-02-28

8.  Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.

Authors:  S T Harris; E F Eriksen; M Davidson; M P Ettinger; A H Moffett; D J Baylink; C E Crusan; A A Chines
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

9.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Authors:  Dennis M Black; Susan L Greenspan; Kristine E Ensrud; Lisa Palermo; Joan A McGowan; Thomas F Lang; Patrick Garnero; Mary L Bouxsein; John P Bilezikian; Clifford J Rosen
Journal:  N Engl J Med       Date:  2003-09-20       Impact factor: 91.245

10.  Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

Authors:  R Eastell; I Barton; R A Hannon; A Chines; P Garnero; P D Delmas
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

View more
  2 in total

1.  Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.

Authors:  Lindsay M Coe; Srinivasan Arjun Tekalur; Yutian Shu; Melissa J Baumann; Laura R McCabe
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

Review 2.  Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.

Authors:  Teun M Post; Serge C L M Cremers; Thomas Kerbusch; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.